5 Topic Commentaries

Avacincaptad Pegol and Anti-VEGF in Real-World Practice

• 

  Michael F. Chiang, MD

  Ophthalmology

  •

  National Eye Institute (NIH)

  This is truly an exciting time for the field and underscores the importance of basic and translational scientific research. These advances in AMD therapeutics wouldn’t have happened without federal support through funding from the National Eye Institute.

  Source
• 

  Anand Swaroop, PhD

  Retinal genetics and therapy

  •

  National Eye Institute (NIH)

  Small effects of these drugs on GA are not surprising, as these molecules are targeted to one complement component.

  Source
• 

  Emily Y. Chew, MD

  Retina/Ophthalmology

  •

  National Eye Institute (NIH)

  Does the treatment effect continue, accelerate, or does the effect level off? If there is an increase or a maintenance of the treatment effect, one would have greater confidence in the therapy.

  Source
• 

  Rajendra S. Apte, MD, PhD

  Retina/Ophthalmology

  •

  Washington University in St. Louis

  We’re at the very early stages. We have our first therapeutics for GA, but it’s like photodynamic laser therapy for wet AMD, our goal was to reduce the risk of severe vision loss in a subset of patients.

  Source
• 

  Mark H. Nelson, MD

  Retina/Ophthalmology

  •

  Retinanet

  The concept of anti-VEGF treatment failure in Neovascular Age-Related Macular Degeneration (nAMD) is widely used in both clinical practice and the literature.

  Source